We describe a solitary fibrous tumour of the urinary bladder wall removed from a 50–year–old man with a history of pelvic pain, dysuria, and urinary bleeding. Anamnesis revealed a weight increase during the preceding 3 months, but no apparent episodes of biochemical hypoglycaemia or hormonal abnormalities. The patient is alive and well 18 months after surgery. Pathological examination revealed a 6.5–cm well–circumscribed nodular mass composed of uniform spindle cells arranged in bundles and fascicles with varying amounts of collagen and a typical haemangiopericytoma–like vascular pattern. The tumour cells were positive for bcl–2, CD34, and vimentin and ultrastructurally showed mesenchymal–myofibroblastic traits. These cells produced insulin–like growth factor type II mRNA as demonstrated by non–isotopic in situ hybridization. This rare case with a solitary fibrous tumor suggests that insulin–like growth factor type II could join CD34 and bcl–2 as markers for postoperative differential diagnosis.

Keywords:
Urinary bladder, Solitary fibrous tumour, Immunohistochemical analysis, Insulin–like growth factor type II
1.
England DM, Hochholzer L, McCarthy MJ: Localized benign and malignant firbous tumors of the pleura: A clinicopathologic review of 223 cases. Am J Surg Pathol 1989;13:640– 658.
2.
Van de Rijn M, Lombard CM, Rouse RV: Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum and lung. Am J Surg Pathol 1994;18:814–820.
3.
Safnek JR, Alguacil–Garcia A, Dort JC, Phillips SM: Solitary fibrous tumour: Report of two new locations in the upper respiratory tract. J Laryngol Otol 1993;107:252–256.
4.
Witkin GB, Rosai J: Solitary fibrous tumor of the upper respiratory tract: A report of six cases. Am J Surg Pathol 1991;15:842–848.
5.
Westra WH, Gerald WL, Rosai J: Solitary fibrous tumor: Consistent CD34 immunoreactivity and occurrence in the orbit. Am J Surg Pathol 1994;18:992–998.
6.
Mentzel T, Bainbridge TC, Katekamp D: Solitary fibrous tumour: Clinico–pathological, immunohistochemical, and ultrastructural analysis of 12 cases arising in soft tissues, nasal cavity and nasopharynx, urinary bladder and prostate. Virchows Arch 1997;430:445–453.
7.
Cameselle–Teijeiro J, Valera–Duran J, Fonseca E, Villanueva JP, Sobrinho–Simoes M: Solitary fibrous tumor of the thyroid. Am J Clin Pathol 1994;101:535–538.
8.
Ferreiro AJ, Nascimento GA: Solitary fibrous tumor of the major salivary glands. Histopathology 1996;28:261–264.
9.
Suster S, Nascimento GA, Miettinen M, Sickel ZJ, Moran AC: Solitary fibrous tumors of soft tissue: A clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol 1995;19:1257–1266.
10.
Bernaud R, Arvieux C, Pasquier D, Pasquier B, Letoublon C: Solitary fibrous tumour of the liver with CD34 expression. Histopathology 1996;28:551–554.
11.
el–Naggar AK, Ro JY, Ayala AG, Ward R, Ordonez NG: Localized fibrous tumor of the serosal cavities: Immunohistochemical, electron–microscopic, and flow–cytometric DNA study. Am J Clin Pathol 1989;92:561–565.
12.
Goodland JR, Fletcher CDM: Solitary fibrous tumour arising at unusual sites: Analysis of a series. Histopathology 1991;19:515–522.
13.
Fain JS, Eble J, Nascimento AG: Solitary fibrous tumors of the kidney: Report of 3 cases. J Urol Pathol 1996;4:227–238.
14.
Bainbridge TC, Singh RR, Mentzel T, Katekamp D: Solitary fibrous tumor of urinary bladder: Report of two cases. Hum Pathol 1997;28:1204–1206.
15.
Fischer C, Bisceglia M: Solitary fibrous tumor of the spermatic cord. Br J Urol 1994;74:798– 799.
16.
Cohen PR, Rapini RP, Farhood AI: Expression of the human haematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors. J Cutan Pathol 1993;20:15–20.
17.
Hanau AC, Miettinen M: Solitary fibrous tumour: Histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol 1995; 26:440–449.
18.
Van de Rijn M, Rouse RV: CD34: A review. Appl Immunohistochem 1994;2:71–80.
19.
Chilosi M, Facchetti F, Dei Tos AP, Lestani M, Morassi ML, Martignoni G, Sorio C, Benedetti A, Morelli L, Doglioni C, Barberis M, Menestrina F, Viale G: Bcl–2 expression in pleural and extrapleural solitary fibrous tumors. J Pathol 1997;181:362–367.
20.
Suster S, Fisher C, Moran AC: Expression of bcl–2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22:863–872.
21.
Baxter RC: The role of insuline–line growth factors and their binding proteins in tumor hypoglycaemia. Horm Res 1996;46:195–201.
22.
Drake MW, Miraki F, Siddiqi A, Yateman M, Barnes CN, Camancho–Hubner C, Monson PJ: Dose–related effects of growth hormone on IGF–I and IGF–binding protein–3 levels in non–islet cell tumour hypoglycaemia. Eur J Endocrinol 1998;139:532–536.
23.
Perros P, Simpson J, Innes AJ, Teale DJ, Mcknight AJ: Non–islet cell tumour–associated hypoglycaemia: 111In–octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clin Endocrinol (Oxf) 1996;44:727–731.
24.
Fukasawa Y, Takada A, Tateno M, Sato H, Koizumi M, Tanaka A, Sato T: Solitary fibrous tumor of the pleura causing recurrent hypoglycemia by secretion of insulin–like growth factor II. Pathol Int 1998;48:47–52.
25.
Fiorentino M, Grigioni WF, Baccarini P, D’Errico A, De Mitri MS, Pisi E, Mancini AM: Different in situ expression of insuline–like growth factor type II in hepatocellular carcinoma: An in situ hybridization and immunohistochemical study. Diagn Mol Pathol 1994;3: 59–65.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.